Endocrine Abstracts

Introduction: TKIs including anti-VEGF receptor activity have been approved for the treatment of patients with radioiodine resistant thyroid carcinomas. For lenvatinib arterial thromboembolic events are listed as adverse events of special interest. In the phase III study of SELECT trial, arterial thromboembolic events were reported in 3% of lenvatinib-treated patients and 1% in the placebo group. Most of the patients had predisposing factors. Only one myocardial infarct was re...

Lipoadenoma is an uncommon benign lesión of the parathyroid gland (<1%) and it has most commonly described as non-functional, but also is a very rare cause of primary hyperparathyroidism. Since 1958 scientific literatura had described 54 cases all over the world and only six of that paratyroid lipoadenomas was extended into torax. A case of intrathoracic parathyroid lipoadenoma with hyperparathyroidism is described. A 69–year–old man was refered to our hos...

The diagnosis of atypical non-autoimmune forms of diabetes mellitus, such as maturity onset diabetes of the young (MODY) presents several challenges, in view of the extensive clinical and genetic heterogeneity of the disease. In this report we describe a case of atypical non autoimmune diabetes associated with a damaging HNF1β mutation. A 39-years-old woman with normal weight (BMI 20’8 kg/m2), endometriosis, ex-smoker, fatty liver and uterus bicornis unic...

Acute pancreatitis (AP) is an inflammatory disorder of the pancreas, most commonly caused by gallstones and heavy alcohol consumption. The diagnosis is established with at least 2 of the following criteria: abdominal pain; increased serum lipase/amylase levels greater than 3 times the upper limit of normal value; or characteristic findings on contrast computed tomography (CT). Since the beginning of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic, a few...

Selpercatinib is a receptor tyrosine kinase RET inhibitor for the treatment of cancers such as RET-mutant medullary thyroid cancer, demonstrating partial response and low incidence of serious adverse events. Vandetanib, a tyrosine kinase inhibitor, has shown promising results with an increase in progression-free survival and prolonged lifetime, but it causes adverse events such as hypertension, diarrhea, rash, or long QT interval. Most of them are can be even disabling for the...